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In the old days, non–small-cell lung cancer was simple—there were no effective screen-ing test, no functionally important subtypes, it was a disease of smokers, was rarely cur-
able, and the medical therapy options were limited to nonexistent, and neither familial nor 
somatic genetics was relevant. When diagnosed with lung cancer one of the first ques-
tions acquaintances and physicians ask is “Did you smoke?” expecting a positive answer. 
Many physicians, if they asked about family history in lung cancer patients at all, generally 
ignored the information even if lung cancer was found in first-degree relatives, because of 
the high prevalence of this disease.
Now everything has changed. In the span of a generation, it is now recognized that 
most cases of lung cancer occur in nonsmokers and many in never-smokers. Computed 
tomography screening can detect it early and save lives, and genetically informed therapy 
selection is now standard of care with dramatic clinical benefit usually observed when 
therapy can be matched to specific gene mutations.
However, somatic genetics has not played a role in this revolution to date. Perhaps 
presciently, during discussions of lung cancer genetics in the clinic, informed family mem-
bers who know about breast cancer suseptibility gene (BRCA) testing for breast cancer or 
adenomatous polyposis coli syndrome (APC)/hereditary non polyposis colorectal cancer 
syndrome (HNPCC) testing for colon cancer usually ask me whether this gene mutation 
we have found in the tumor can be passed to their children. Physicians previously could 
confidently say no. The two reports in this issue of Journal of Thoracic Oncology discuss-
ing germline epidermal growth factor receptor (EGFR) T790M,1,2now break this last icon, 
and report a very high risk of lung cancer in never-smoking carriers of this allele. These 
studies now solidify the fact that routine clinical management of lung cancer now has to 
include the awareness of this inherited cancer syndrome. Lung cancer genetic analysis 
should thus routinely include not only EGFR T790M, but also some measure of allele 
frequency, as we have now implemented in the routine genetics reports at my institution. 
Through this awareness over the past several years I have found two unrelated families 
with this syndrome in my own clinical practice, so I am sure the vast majority of these 
cases are currently being missed.
There is, however, much remaining to clarify about this syndrome, both clinically 
and scientifically. Because it is currently most often detected in lung cancer patients, the 
most pressing questions are two: defining the optimal acute and chronic management of 
lung cancer in these people, and clarification of the penetrance and optimal management 
of affected family members. For the first question, it seems clear that these patients are 
likely to respond differently to first-generation EGFR tyrosine kinase inhibitors (TKIs) than 
nongermline patients, and testing of the latest generation of T790M selective inhibitors for 
therapy is an obvious choice. In addition, exclusion or stratification of these patients from 
patients without germline T790M is imperative in clinical trials targeting this gene.
Less obvious is how to manage family members, including children, inheriting this gene. 
This can only be clarified by prospective studies such as the ongoing Addario Lung Cancer 
Medical Institute–sponsored Investigating Hereditary Risk for T790M (INHERIT) trial, and 
it is important to enroll patients in this trial to improve our understanding of this syndrome. 
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A reasonable step to take now is to add carrier status as an eli-
gibility criterion for low-dose computed tomography screening, 
but it is completely unclear at what age to start this screening, 
as although most cases would fall in the age range of 55 to 70 
years, cases in much younger patients have been identified. 
Management of patients with sometimes multiple ground-glass 
lesions is complicated under the best of circumstances, but more 
so when the patient is known to have a germline T790M. Current 
practice of intervening only when these lesions start to turn solid 
is reasonable, but demands prospective study. One exciting pos-
sibility is to initiate a clinical trial using one of the new T790M 
selective drugs as chemopreventives in this population.
There are many other unanswered questions, including 
the effect of this allele on the development of other cancers. 
Both of the families I have identified also have a large number 
of breast cancer cases, as was the case in one of the families 
studied by Yu et al.,1 begging the question of whether the inci-
dence of breast cancer may be increased in carriers. Clinical 
geneticists now need to be made aware of this syndrome for 
them to be informed and partner with oncologists in following 
these patients and their families.
Many intriguing scientific questions remain unan-
swered. Linkage studies to study founder effects would be 
interesting, but most interesting to me is explaining the fact 
that this same exact amino acid substitution is the most fre-
quently acquired resistance mutation after therapy with TKIs, 
and is even present at subclonal levels in some tumors before 
therapy, portending a worsened progression-free survival. The 
fraction of tumor cells with this allele seems to increase dur-
ing therapy and decrease if the selection pressure is removed, 
suggesting some disadvantage to clones with both traditional 
activating and T790M alleles. Thus this allele seems to be 
both tumor-promoting and tumor-inhibiting, depending on the 
context. What is special about this alteration that it not only 
persists in the germline in multiple populations, but also is 
apparently strongly and specifically selected for after therapy 
with TKIs? These two observations are not likely to be the 
result of chance, but more likely some key unknown function 
of this alteration or feature of the DNA or chromatin at this 
location in the genome that drives this convergent evolution.
Lung cancer has thus grown up from a depressing, 
monotonous, and uniformly awful disease to one in which, 
while still frequently awful, there is a rapidly advancing 
molecular understanding, rationally targeted therapeutics, 
effective screening, and now improving risk stratification 
including germline genetics. It has been an exciting ride.
REFERENCES
 1. Yu A, Arcila M, Fleischut, MH, et al. Germline EGFR T790M muta-
tion found in multiple members of a familial cohort. J Thorac Oncol 
2014;9(4): 554–558.
 2. Gazdar A, Robinson L, Oliver D, et al. Hereditary lung cancer syndrome 
targets never smokers with germline EGFR gene T790M mutations. 
J Thorac Oncol 2014;9(4): 456–463.
